EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Everolimus-Eluting Stents or Bypass Surgery for Multivessel Disease in Diabetics

Hoyun Kim, Do-Yoon Kang, Jung-Min Ahn, Jinho Lee, Yeonwoo Choi, Seung Ho Hur, Hun-Jun Park, Damras Tresukosol, Woong Chol Kang, Hyuck Moon Kwon, Seung-Woon Rha, Do-Sun Lim und 12 weitere

JACC: Cardiovascular Interventions · 2023

DOI: 10.1016/j.jcin.2023.07.028 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JACC: Cardiovascular Interventions, 2023. Verfasst von Hoyun Kim und 23 weiteren Autor:innen. Beteiligte Einrichtung: Heart Institute, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Coronary Artery Disease, Drug-Eluting Stents, Percutaneous Coronary Intervention, Myocardial Infarction. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: Korea Ministry of Health and Welfare.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Diabetes mellitus is associated with more complex coronary artery diseases. Coronary artery bypass grafting (CABG) is a preferred revascularization strategy over percutaneous coronary intervention (PCI) in diabetics with multivessel coronary artery disease (MVD). OBJECTIVES: This study sought to examine the different prognostic effects of revascularization strategies according to the diabetes status from the randomized BEST (Randomized Comparison of Coronary Artery Bypass Surgery and Everolimus-Eluting Stent Implantation in the Treatment of Patients With Multivessel Coronary Artery Disease) trial. METHODS: Patients (n = 880) with MVD were randomly assigned to undergo PCI with an everolimus-eluting stent vs CABG stratified by diabetics (n = 363) and nondiabetics (n = 517). The primary endpoint was the composite of death, myocardial infarction, or target vessel revascularization during a median follow-up of 11.8 years (IQR: 10.6-12.5 years). RESULTS: In diabetics, the primary endpoint rate was significantly higher in the PCI group than in the CABG group (43% and 32%; HR: 1.53; 95% CI: 1.12-2.08; P = 0.008). However, in nondiabetics, no significant difference was found between the groups (PCI group, 29%; CABG group, 29%; HR: 0.97; 95% CI: 0.67-1.39; P = 0.86; Pinteraction= 0.009). Irrespective of the presence of diabetes, no significant between-group differences were found in the rate of a safety composite of death, myocardial infarction, or stroke and mortality rate. However, the rate of any repeat revascularization was significantly higher in the PCI group than in the CABG group. CONCLUSIONS: In diabetics with MVD, CABG was associated with better clinical outcomes than PCI. However, the mortality rate was similar between PCI and CABG irrespective of diabetes status during an extended follow-up. (Ten-Year Outcomes of Randomized Comparison of Coronary Artery Bypass Surgery and Everolimus-Eluting Stent Implantation in the Treatment of Patients With Multivessel Coronary Artery Disease [BEST Extended], NCT05125367; Randomized Comparison of Coronary Artery Bypass Surgery and Everolimus-Eluting Stent Implantation in the Treatment of Patients With Multivessel Coronary Artery Disease [BEST], NCT00997828).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Coronary Artery DiseaseDrug-Eluting StentsPercutaneous Coronary InterventionMyocardial InfarctionDiabetes MellitusHumansFollow-Up StudiesEverolimusTreatment OutcomeStents

Stichwörter der Autor:innen

bypass surgerycoronary interventiondiabetesmultivessel diseasestent(s)

Substanzen

Everolimus

Autor:innen und Institutionen

  • Heart Institute, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Heart Institute, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. Electronic address: drjmahn@gmail.com.
  • Keimyung University Dongsan Medical Center, Daegu, Korea.
  • Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Korea.
  • Siriraj Hospital, Bangkok, Thailand.
  • Gachon University Gil Hospital, Incheon, Korea.

Förderung

  • Korea Ministry of Health and Welfare

Zitieren

APA

Kim, H., Kang, D. Y., Ahn, J. M., Lee, J., Choi, Y., Hur, S. H., Park, H. J., Tresukosol, D., Kang, W. C., Kwon, H. M., Rha, S. W., Lim, D. S., Jeong, M. H., Lee, B. K., Huang, H., Lim, Y. H., Bae, J. H., Kim, B. O., Ong, T. K., …, & BEST Extended Follow-Up Study Investigators (2023). Everolimus-Eluting Stents or Bypass Surgery for Multivessel Disease in Diabetics. JACC: Cardiovascular Interventions. https://doi.org/10.1016/j.jcin.2023.07.028

Vancouver

Kim H, Kang DY, Ahn JM, Lee J, Choi Y, Hur SH, et al. Everolimus-Eluting Stents or Bypass Surgery for Multivessel Disease in Diabetics. JACC: Cardiovascular Interventions. 2023. doi:10.1016/j.jcin.2023.07.028

BibTeX
@article{Kim2023,
  author = {Kim, Hoyun and Kang, Do-Yoon and Ahn, Jung-Min and Lee, Jinho and Choi, Yeonwoo and Hur, Seung Ho and Park, Hun-Jun and Tresukosol, Damras and Kang, Woong Chol and Kwon, Hyuck Moon and Rha, Seung-Woon and Lim, Do-Sun and Jeong, Myung-Ho and Lee, Bong-Ki and Huang, He and Lim, Young-Hyo and Bae, Jang Ho and Kim, Byung Ok and Ong, Tiong Kiam and Ahn, Sung Gyun and Chung, Cheol-Hyun and Park, Duk-Woo and Park, Seung-Jung and BEST Extended Follow-Up Study Investigators, BEST Extended Follow-Up Study Investigators},
  title = {Everolimus-Eluting Stents or Bypass Surgery for Multivessel Disease in Diabetics},
  journal = {JACC: Cardiovascular Interventions},
  year = {2023},
  doi = {10.1016/j.jcin.2023.07.028}
}
Kostenlos starten →